ASCO 2019: Lynparza beats chemotherapy in relapsed BRCA-mutated advanced ovarian cancer
Anglo-Swedish pharma major AstraZeneca (LSE: AZN) and US drug giant Merck & Co (NYSE: MRK) have presented further evidence in support of Lynparza (olaparib) at the 2019 ASCO meeting.
Based on results in the Phase III SOLO3 trial, Lynparza is the first PARP inhibitor to demonstrate efficacy over chemotherapy in relapsed BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy.
"We look forward to working closely with regulatory authorities to include findings from this trial in the prescribing information"There was a statistically-significant and clinically-meaningful improvement in objective response rate, as there was in progression-free survival, with Lynparza patients living without the disease advancing for an average of four months longer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze